Top Pharmaceutical Companies in Los Angeles, CA (79)
GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...
GoodRx's Top Stability & Growth Strengths
Product Line Growth: Newer businesses such as Pharma Direct and subscriptions are expanding rapidly, with clear momentum highlighted in 2026. Investment is being shifted toward these lines to replace slower legacy revenue.
Future-Ready Strategy: Management is prioritizing Pharma Direct and subscription products and raised 2026 revenue guidance, signaling a transition aimed at restoring overall growth. These segments are described as the main engines expected to offset declines in the legacy business.
Profitability: Profitability remains solid even as the top line fluctuates, including positive GAAP earnings and substantial adjusted EBITDA in Q2 2026. Operating cash flow also strengthened, supporting continued execution.
Mixlab is the first modern, tech-enabled pet pharmacy that focuses on creating custom medications and delightful experiences for pets, their parents and veterinarians. By putting service at the heart of everything we do, our talented team is able to provide the best personalized care for our patients, as well as those who care for them.
Mixlab's Top Stability & Growth Strengths
Market Expansion: The company expanded from a few labs to a multi‑site footprint across NY, CA, FL, TX, and WI with shipping to all 50 states and same‑/next‑day options in select markets. Acquisitions in 2024–2025 (e.g., NexGen, The Pet Apothecary, SBH Medical’s veterinary business) broadened geographic coverage and capacity.
Investor Backing & Capital Strength: Recent capital raises, including a $10M round in 2023, funded nationwide scaling and platform development. Investor support is tied to new facilities and acquisitions that extend operational reach.
Innovation-Driven Growth: Technology integrations (e.g., Vetcove, Vetsource, Instinct EMR), a new client portal, and launch of an AI health partner (Maisy) underpin a tech‑first growth strategy. The model emphasizes a modern, veterinary‑friendly digital workflow and fast fulfillment.
Tarsus is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients with unmet needs.
American Regent, Inc., a Daiichi Sankyo Group Company, is a leading manufacturer of generic and branded specialty sterile injectable products. Dedicated to improving human and animal health, the company develops, manufactures, and supplies high-quality injectables for healthcare providers, clinics, and hospitals across the United States and Canada. Their expansive portfolio includes a strong focus on IV iron therapy and other...
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to...
Medspas are booming, and are often a path for individual nurses to become business owners. We believe that’s a good thing for them, their communities, local economies, and clients. We unlock the entrepreneurial opportunity in aesthetics for those with the moxie to take the leap. Moxie gives aesthetic entrepreneurs everything they need to successfully compete (and win) against even the biggest...
Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive...
Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the...
Insulet's Top Stability & Growth Strengths
Strong Revenue Growth: Company reported accelerating revenue growth across 2024–2025 and guided continued double‑digit expansion for 2026. Quarterly updates highlighted broad‑based momentum in both U.S. and international markets.
Strong Market Position & Advantage: Omnipod leads the tubeless/patch‑pump segment and ranked No. 1 in new customer starts in the U.S. and Europe in 2024–2025, reinforcing competitive momentum. First‑to‑market AID clearance for adults with type 2 diabetes and broad CGM integrations bolster positioning.
Market Expansion: International rollouts and expansion into type 2 diabetes materially increased the addressable market and active user base. Added manufacturing capacity in Malaysia supports global demand and cost scaling.
Best Formulations is a contract manufacturer specializing in the development and production of nutraceuticals, dietary supplements, and personal care products. Founded in 1984, the company provides manufacturing services for vitamins, minerals, and plant-based nutritional supplements. Following its acquisition by Sirio Pharma, it serves as a key manufacturing hub for global health and wellness brands, with operations spanning nutraceuticals and beauty...
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
Edwards Lifesciences (NYSE: EW), is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales &...
Edwards Lifesciences's Top Stability & Growth Strengths
Strong Market Position & Advantage: Edwards is broadly characterized as the TAVR category leader anchored by the SAPIEN portfolio, and its first-to-approval EVOQUE tricuspid replacement reinforces leadership across structural heart. Industry trackers and company updates point to durable share and breadth across aortic, mitral, and tricuspid therapies.
Strong Revenue Growth: Recent results show double-digit top-line expansion and successive raises to the 2026 sales outlook, driven by steady TAVR demand and rapid TMTT growth. Management commentary emphasizes continued momentum with a consistent long-term growth ambition.
Innovation-Driven Growth: First-to-approval EVOQUE in tricuspid replacement, rapid uptake of PASCAL in mitral repair, and extensive long-term SAPIEN evidence position the portfolio for further adoption. Regulatory and policy catalysts, including a pending CMS TAVR coverage reconsideration and accumulating durability data, may expand access.
A global leader in developing and producing responsible packaging for food, beverage, pharma, medical, home- and personal-care, and other products. Amcor works with leading companies around the world to protect their products and the people who rely on them, differentiate brands, and improve supply chains through a range of flexible and rigid packaging, specialty cartons, closures, and services. The company...
PolyPeptide is a global Contract Development and Manufacturing Organization (CDMO) specializing in the development and manufacturing of peptide-based active pharmaceutical ingredients (APIs) and oligonucleotides. Serving pharmaceutical and biotech customers worldwide, the company supports the creation of therapies for metabolic diseases, cancer, and neurological disorders, contributing to the health of millions of patients through deep technical expertise and GMP-quality production.
Aadi Bioscience Inc. (Aadi) is a biopharmaceutical company focused on precision therapies for genetically-defined cancers. We strive to unleash the potential of mTOR inhibition by employing precision medicine & nanoparticle technology to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Our lead product has been FDA-approved for the treatment of adult patients with locally advanced unresectable or...
Varda Space Industries was founded in 2020 with the goal of manufacturing products in space to benefit life on Earth. Co-founders Will Bruey and Delian Asparouhov imagined a world where space could be leveraged not only for storytelling and awe, but for its economic benefits. Varda was created as a platform for in-space manufacturing, with a range of real-life, on-Earth...
We are alchemists at heart, harnessing science to create powerful wellness solutions. The combination of alchemy and “me” offers the right mixture of science, expertise, and support that empowers our customers with confidence. Through one-of-a-kind expert-designed formulas and positive guidance, Alchemee provides solutions that are as effective as they are transformative. At Alchemee, we are committed to empowering the world one person at a...
In 1971, Pharmavite pioneered the VMS category by creating quality supplements backed by science that offer consumers meaningful solutions to support their personal health and fill key nutrient gaps. Our sole purpose then and now is to bring the gift of health to life, by helping people achieve a healthier way of living. This purpose is our passion and priority. Driven by...
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our pipeline includes tipifarnib, a farnesyl...
